This trial is completed!
Search for a recruiting clinical trial for your condition
Your journey
1What's a trial
2Find
3Review
4Get in touch
More info
You can access this
clinical trial
if you have
Lymphoma, Large B-Cell, Diffuse
and you are
over 18
years old
3
This is a trial in the final phase before the treatment is released on the market.
Show me locations

The purpose

The aims of this study are: - To evaluate the benefits of the addition of bortezomib to standard rituximab with cyclophosphamide, doxorubicin, vincristine, prednisolone (R-CHOP) therapy in Diffuse Large B-cell Lymphoma (DLBCL). - To determine whether molecular phenotype effects the benefits derived from the addition of bortezomib.

Provided treatments

  • Drug: Intravenous
  • Drug: Bortezomib

Locations near you

Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Tris trial is registered with FDA with number: NCT01324596. The sponsor of the trial is University Hospital Southampton NHS Foundation Trust and it is looking for 1132 volunteers for the current phase.
Official trial title:
A Randomised Evaluation of Molecular Guided Therapy for Diffuse Large B-cell Lymphoma With Bortezomib